We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.
- Authors
Curry, M. P.; Tapper, E. B.; Bacon, B.; Dieterich, D.; Flamm, S. L.; Guest, L.; Kowdley, K. V.; Lee, Y.; Milligan, S.; Tsai, N.; Younossi, Z.; Afdhal, N. H.
- Abstract
Background Treatment of genotype 1 hepatitis C virus ( HCV) infection with combination direct acting anti-virals is associated with very high rates of sustained virological response ( SVR). Daily combination of ledipasvir and sofosbuvir for 12 weeks is approved for the treatment of genotype 1 HCV patients, though noncirrhotic patients who are naïve to treatment with a baseline HCV RNA <6 million IU/mL can be treated for 8 weeks. This guidance stemmed from a post hoc analysis of the ION 3 clinical trial, which demonstrated similar SVR for patients treated with ledipasvir and sofosbuvir with or without ribavirin for 8 or 12 weeks. Aim To compare the SVR for 8 weeks vs 12 weeks of ledipasvir and sofosbuvir in HCV infected patients in a real-world setting. Methods We performed an observational real-world cohort study of treatment success following 8 or 12 weeks of ledipasvir and sofosbuvir for treatment-naïve genotype 1 HCV patients. Results A total of 826 patients were treated for either 8 (n=252) or 12 weeks (n=574) with ledipasvir and sofosbuvir and achieved SVR rate of 95.3% and there was no statistical difference in SVR rates in the two groups irrespective of any clinical or virological variables. Conclusions In treatment-naïve HCV genotype 1 patients, SVR was 95% in those treated for either 8 weeks or 12 weeks with ledipasvir and sofosbuvir. 8 week ledipasvir and sofosbuvir can reduce costs without compromising outcomes for those patients who qualify for such regimen.
- Subjects
SOFOSBUVIR; DRUG efficacy; ANTIVIRAL agents; HEPATITIS C; RIBAVIRIN; PATIENTS
- Publication
Alimentary Pharmacology & Therapeutics, 2017, Vol 46, Issue 5, p540
- ISSN
0269-2813
- Publication type
Article
- DOI
10.1111/apt.14204